ArticleTomography (Ann Arbor, Mich.)2026
Differentiation of Adrenal Adenomas from Non-Adenomatous Lesions: Diagnostic Value of Unenhanced Spectral CT.
Article in Tomography (Ann Arbor, Mich.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiating adrenal adenomas from non-adenomatous lesions remains a critical challenge in the management of adrenal incidentalomas. Conventional unenhanced CT relies on attenuation thresholds of 10 HU and 20 HU, which present trade-offs between sensitivity and specificity.
objectivesTo evaluate the diagnostic performance of unenhanced Spectral CT using the attenuation difference between 40 keV and 140 keV virtual monoenergetic images for differentiating adrenal adenomas from non-adenomatous lesions.
methodsIn this retrospective single-center study, 60 patients with adrenal lesions who underwent unenhanced dual-energy CT were included. Mean attenuation values were measured on conventional images and on virtual monoenergetic images at 40 keV and 140 keV. The spectral attenuation difference (Δ40-140 keV) was calculated. ROC analysis was performed to determine the optimal threshold and diagnostic performance. Additional analyses included DeLong comparison of correlated ROC curves and bootstrap resampling to estimate 95% confidence intervals for the area under the curve.
resultsForty-nine lesions were adenomas and eleven were non-adenomatous. The optimal threshold for Δ40-140 keV was -17 HU. When evaluated as a continuous variable, Δ40-140 keV yielded an area under the curve of 0.940 (95% confidence interval: 0.851-1.000), compared with 0.939 (95% confidence interval: 0.870-0.992) for conventional unenhanced attenuation. DeLong comparison showed no statistically significant difference between the two curves (
conclusionsUnenhanced Spectral CT using Δ40-140 keV improves discrimination between adrenal adenomas and non-adenomatous lesions compared with conventional attenuation thresholds. This technique may reduce indeterminate findings and limit the need for additional imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.